Oncotarget Volume 11 Issue 15 reported that P-cadherin-LP-DART is a bispecific antibody targeting P-cadherin expressed on the tumor cells and CD3 on the T-cells.
P-cadherin-LP-DART accumulation in the tumor was 20-25 fold higher compared to Control-LP-DART demonstrating the targeting specificity.
Imaging after engraftment of CV815 labeled T-cells showed P-cadherin-LP-DART mediated T-cell trafficking in tumors.
Dr. Anand Giddabasappa from Global Science & Technology (GST) – Comparative Medicine, Pfizer Global Research Development and Medical, San Diego, CA 92121, USA said, "Antibody-based therapeutic platforms have revolutionized the biopharmaceutical landscape in last two decades."
"Antibody-based therapeutic platforms have revolutionized the biopharmaceutical landscape in last two decades."
- Dr. Anand Giddabasappa, Global Science & Technology (GST) – Comparative Medicine, Pfizer Global Research Development and Medical
Immune effector cells that can be engaged by bispecific antibodies include T cells, Natural Killer cells, and Macrophages.
Mechanistically, bispecific antibodies targeting effector T cells co-engage the CD3 epsilon subunit on the T cells and specific antigen on tumor cells to form a bispecific mediated synapse.
However, the development of these next-generation biologics is increasingly complex and often requires intricate protein engineering approaches to create novel scaffolds and technology platforms.
The bispecific antibody formats can be broadly categorized as:
- A) conventional Ig G like bispecific antibodies that retain Fc-mediated effector antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity functionalities or
- B) novel non-Ig G like bispecific antibodies that generally have dual binding functionality with minimal or no effector functions.
The dual-affinity re-targeting platform is a bispecific molecular format that can co-engage the TCR/CD3 complex on effector T cells and a targeting antigen on tumor cells.
P-cadherin LP-DART is a bispecific molecule that uses the DART platform to bind CD3 epsilon on the T cells and P-cadherin on the tumor cells.
The Umetani/Wu Research Team concluded in their Oncotarget Research Paper that the pharmacology of the bispecific antibody is elicited by forming a bridge between the target cell and the effector cell.
Advances in immunotherapy, along with the interest in tracking immune cells in vivo in patients and in pre-clinical models, has resulted in the development of multiple molecular imaging methodologies.
Figure 1: Schematic of the bispecific reagents used in this study. (A) Representation of the individual chains of anti-P-cadherin human IgG1 Fc-containing DART, also referred to as P-cadherin LP-DART. Cysteine residues introduced for interchain disulfide formation are indicated by C. EFN, effector function null mutations in CH2. Knob, hole: complementary mutations introduced to force Fc heterodimerization [10–12]. (B) Schematic representation of the folded P-cadherin LP-DART protein after heterodimerization. (C) Representation of the anti-P-cadherin single chain diabody (scDb) DART linear expression construct. Cysteine residue introduced for site specific conjugation at the C-terminus is indicated by C. (D) Schematic representation of the folded anti-P-cadherin DART (scDb) protein.
Although CV815 based T cell tracking has several advantages, it may underestimate the number of T cells since the fluorescence is diluted by one-half at each subsequent division of the proliferating T cell.
In summary, using FMT imaging we have shown the targeting of P-cadherin LP-DART and the trafficking of T cells to the tumor microenvironment in pre-clinical models.
Sign up for free Altmetric alerts about this article
DOI - https://doi.org/10.18632/oncotarget.27544
Full text - https://www.oncotarget.com/article/27544/text/
Correspondence to - Anand Giddabasappa - anand.giddabasappa@pfizer.com
Keywords - bispecific antibody, tumor targeting, biodistribution, T cells, molecular imaging
About Oncotarget
Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105
